Next-generation psychedelics: should new agents skip the trip?
Nature Biotechnology June 1, 2024 Peer reviewed DOI: 10.1038/s41587-024-02285-1 via Springer Nature
Summary
Companies are successfully attracting venture funding for new psychedelic drugs and achieving important milestones in clinical trials. This indicates a growing interest and investment in the development of these therapies.
Study at a glance
| Key finding | Companies are attracting venture funding and reaching clinical trial milestones for redesigned psychedelic drugs. |
|---|
Abstract
Companies attract venture funding for redesigned psychedelic drugs and notch clinical trial milestones.